arrow_back Back Filing freshness 10-Q FY 2025 SEC EDGAR

download Export Data

CNS Pharmaceuticals, Inc.

CNSP

$5.46 0.00 (0.00%) at close

9 Visible periods

21 Metrics

Absolute Benchmarks

Price Chart

Health

Poor

Bearish Absolute basis

auto_awesome

Analytical Summary

On an absolute basis, CNS Pharmaceuticals, Inc. shows weak fundamentals, weighed down by Return on Invested Capital and Interest Coverage. These readings use fixed quality thresholds rather than peer benchmarks, because too few comparable companies are available to rank against.

Market Cap $2.4M

Dividend Yield —

Revenue Growth —

Op. Margin —

ROIC -279.3% ↘

FCF / Share $-31.19

Trailing P/E —

Price / Book 0.8x

FCF Yield —

Debt / Equity —

info Valuation on last close. End-of-day price, Aug 4, 2026.

9-Year Financial Trajectory

Annual

Metric Value Trend Year over Year Percentile

Net Income Profit after all expenses

$-15.85M

↓ -6.7% —

FCF / Share Free cash flow per share

$-31.19

↓ -730.8% —

info Signals below are graded against fixed quality thresholds, not peers — peer ranking needs more comparable companies.

trending_up

Bullish Indicators

No bullish signals detected.

warning

Bearish Risks

Return on Invested CapitalReturn on Invested Capital of -279.3% is weak on an absolute basis (target > 10%)
Interest CoverageInterest Coverage of -1047.13x is weak on an absolute basis (target > 5x)
FCF / Net IncomeFCF / Net Income of 0.87x is caution on an absolute basis (target > 1x)

Health Breakdown

Financial Health ↑

Cash Quality ↓

Financial view

Statement lens

Choose the reporting cadence, isolate a period range, or search directly for a metric.

Cadence

Annual Quarterly

Range

→

📈 Is growth accelerating? 3 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗	FY 2017 Dec 31, 2017 10-K ↗
EPS Growth YoY (%)	92.3% Excellent ↑ Excellent Improving Year-over-year change in earnings per share Optimal: > 10%	-9237.8% Weak ↓ Weak Declining Year-over-year change in earnings per share Optimal: > 10%	55.4% Excellent Excellent Year-over-year change in earnings per share Optimal: > 10%	32.0% Excellent Excellent Year-over-year change in earnings per share Optimal: > 10%	—	—	—	—	—
Net Income Growth YoY (%)	-6.7% Weak ↓ Weak Declining Year-over-year change in net income	21.2% Good ↑ Good Improving Year-over-year change in net income	-23.4% Weak ↑ Weak Improving Year-over-year change in net income	-5.4% Weak ↑ Weak Improving Year-over-year change in net income	-53.3% Weak ↓ Weak Declining Year-over-year change in net income	-143.9% Weak Weak Year-over-year change in net income	47.5% Excellent Excellent Year-over-year change in net income	—	—
FCF Growth YoY (%)	—	—	51.6% Excellent Excellent Year-over-year change in free cash flow	49.7% Excellent Excellent Year-over-year change in free cash flow	—	—	—	—	—

💰 Are margins durable? 1 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗	FY 2017 Dec 31, 2017 10-K ↗
FCF / Net Income (x)	0.87x Caution → Caution Stable Free cash flow relative to reported net income Optimal: > 1x	1.15x Fair ↑ Fair Improving Free cash flow relative to reported net income Optimal: > 1x	0.75x Caution ↓ Caution Declining Free cash flow relative to reported net income Optimal: > 1x	0.69x Weak ↓ Weak Declining Free cash flow relative to reported net income Optimal: > 1x	0.93x Caution ↑ Caution Improving Free cash flow relative to reported net income Optimal: > 1x	0.78x Caution ↑ Caution Improving Free cash flow relative to reported net income Optimal: > 1x	0.92x Caution Caution Free cash flow relative to reported net income Optimal: > 1x	0.10x Weak Weak Free cash flow relative to reported net income Optimal: > 1x	—

🎯 Is capital allocation efficient? 3 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗	FY 2017 Dec 31, 2017 10-K ↗
Return on Invested Capital (%)	-279.3% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-190.6% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	336.3% Excellent ↑ Excellent Improving Return earned on debt + equity capital invested Optimal: > 10%	-148.3% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-185.7% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-53.5% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-39.8% Weak Weak Return earned on debt + equity capital invested Optimal: > 10%	126.8% Excellent Excellent Return earned on debt + equity capital invested Optimal: > 10%	—
Return on Capital (%) (%)	-185.4% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-171.3% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-1109.2% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-117.0% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-165.4% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-59.6% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-48.4% Weak Weak Operating profit relative to total assets Optimal: > 10%	-129.0% Weak Weak Operating profit relative to total assets Optimal: > 10%	—
Return on Common Equity (%) (%)	—	-240.5% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-1704%)	—	-187.8% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-1352%)	-235.2% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-1668%)	-67.8% Weak Weak Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-552%)	-51.0% Weak Weak Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-440%)	—	—

⚖️ Is the balance sheet risky? 4 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗	FY 2017 Dec 31, 2017 10-K ↗
Debt to Equity (x)	—	—	—	0.06x Excellent ↑ Excellent Improving Total debt relative to shareholder equity Optimal: < 0.6x vs Sector: Below avg (-91%)	0.07x Excellent Excellent Total debt relative to shareholder equity Optimal: < 0.6x vs Sector: Below avg (-88%)	0.03x Excellent Excellent Total debt relative to shareholder equity Optimal: < 0.6x vs Sector: Below avg (-94%)	—	—	—
Interest Coverage (x)	-1047.13x Weak ↑ Weak Improving Operating income divided by interest expense Optimal: > 5x	-1095.81x Weak ↑ Weak Improving Operating income divided by interest expense Optimal: > 5x	-1366.54x Weak ↑ Weak Improving Operating income divided by interest expense Optimal: > 5x	-2172.64x Weak ↓ Weak Declining Operating income divided by interest expense Optimal: > 5x	-1560.14x Weak ↓ Weak Declining Operating income divided by interest expense Optimal: > 5x	-2896.63x Weak ↓ Weak Declining Operating income divided by interest expense Optimal: > 5x	-146.57x Weak Weak Operating income divided by interest expense Optimal: > 5x	-30.82x Weak Weak Operating income divided by interest expense Optimal: > 5x	—
Net Debt (USD)	$-7.20M	$-6.46M	$-548.72K	$-9.61M	$-4.58M	$-13.56M	$-7.24M	$-282.74K	—
Debt / EBITDA (x)	—	—	—	-0.03x Excellent ↑ Excellent Improving Debt relative to earnings before interest, taxes, depreciation Optimal: < 2x	-0.03x Excellent Excellent Debt relative to earnings before interest, taxes, depreciation Optimal: < 2x	-0.05x Excellent Excellent Debt relative to earnings before interest, taxes, depreciation Optimal: < 2x	—	—	—

📊 What does each share earn? 5 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗	FY 2017 Dec 31, 2017 10-K ↗
Basic EPS, GAAP (USD)	$-35.75	$-466.89	$-5.00	$-11.22	$-16.50	—	—	—	—
Free Cash Flow per Share (USD)	$-31.19	—	$-3.75	$-7.76	$-15.42	—	—	—	—
Book Value per Share (USD)	$7.15	$52.43	$-0.71	$5.03	$6.49	$0.58	$0.46	$-0.04	—
Tangible Book Value per Share (USD)	$7.15	$52.43	$-0.71	$5.03	$6.49	$0.58	$0.46	$-0.04	—
Basic Weighted Avg Shares (shares)	443,369	31,823	3.77M	1.36M	878,443	—	—	—	—

🏦 How resilient is the balance sheet? 2 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗	FY 2017 Dec 31, 2017 10-K ↗
Working Capital (USD)	$4.00M	$6.13M	$-4.54M	$7.64M	$4.88M	$13.59M	$7.58M	$-644.50K	—
Total Equity (USD)	$4.52M	$6.18M	$-4.43M	$8.13M	$6.16M	$13.95M	$7.60M	$-549.30K	$-58.53K

📋 What is driving earnings? 3 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗	FY 2017 Dec 31, 2017 10-K ↗
Depreciation Expense (USD)	$3.92K	$3.31K	$4.13K	$11.76K	$13.07K	$11.10K	$1.96K	$0.00	—
Net Income, GAAP (USD)	$-15.85M	$-14.86M	$-18.85M	$-15.27M	$-14.50M	$-9.46M	$-3.88M	$-7.39M	—
Operating Cash Flow (USD)	$-13.81M	$-17.11M	$-14.14M	$-10.56M	$-13.54M	$-7.32M	$-3.55M	$-716.38K	—

⌨️ Keyboard Shortcuts

/ Search

Esc Clear

A Annual

Q Quarterly

1-7 Jump to category

R Reset

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 9 years · 34 quarters

CNS Pharmaceuticals, Inc.

Analytical Summary

9-Year Financial Trajectory

Bullish Indicators

Bearish Risks

Health Breakdown

Statement lens

Benchmark Lens

Benchmarks unavailable

Compare CNSP with peers